Parent briefing: fifth measles death, RSV day one, leftover recalls

1 October 2026, morning briefing. Three things parents can act on today: Pennsylvania’s fifth measles-associated death and the still-open count gap with CDC, day one of the continental RSV antibody window, and leftover button-battery and sleep-machine recalls.

Measles: 943 cases, a fifth death, and a dashboard that does not match

On 30 September the Pennsylvania Department of Health reported that an unvaccinated Lancaster County resident with confirmed measles had died. The state counts this as the fifth measles-associated death of 2026. Cumulative cases stood at 943 across 39 counties, with 176 hospitalizations and 40 new cases since 28 September. Four cases — under 1 percent — were in vaccinated people. Two earlier Lancaster deaths were infants.

CDC’s national dashboard had confirmed only two measles deaths as of late September, after a dispute with the state over what counts as a measles death. Parents should treat the state definition and the CDC count as different ledgers, not as proof the deaths did not happen. MMR remains about 97 percent effective after two doses. Pennsylvania providers gave more than 53,000 doses in September, more than double a typical month of about 25,000.

If you are pregnant, have an infant under 12 months, or cannot find two documented MMR doses, call the clinic before a routine visit if you live in or recently traveled through an outbreak county. Infants are not routinely vaccinated until 12 months; outbreak guidance can move the first dose earlier. People who think they were exposed and have fever, cough, runny nose, red eyes, or a rash that starts at the head should call ahead — 877-PA-HEALTH in Pennsylvania — rather than sit in a waiting room.

RSV: the antibody window opened today

For most of the continental United States, AAP timing for nirsevimab (Beyfortus) and clesrovimab (Enflonsia) is 1 October through 31 March. Infants under 8 months entering their first season qualify if the birthing parent did not get RSVpreF in pregnancy, vaccination status is unknown, or the baby was born fewer than 14 days after that dose. A dose in the first week of life, ideally before hospital discharge, is the AAP preference for babies born in season.

Second-season protection (8 through 19 months) is only for higher-risk children, and only nirsevimab is indicated for that dose. Beginning this season AAP expanded that list to include children born before 32 weeks, significant heart disease, certain lung or neuromuscular conditions, and Down syndrome or other chromosomal differences that raise RSV risk. A first-season dose does not replace a second-season dose for those children.

Still-open product hazards

Love to Dream portable sleep machines (about 4,000 units, recall 24 September) can overheat. Stop use and follow the CPSC refund steps. Skip Hop Sesame Street Elmo silicone teethers (recall 3 September) can shed the black eyes if frozen — do not freeze them. ABC Trading and ZMC Group light-up toys still fail the button-battery rule; a swallowed coin cell can burn the esophagus within hours. XIOYIG infant walkers are a stop-use warning, not a refund recall: they fit through a doorway and do not stop at a step.

This is a parent briefing, not personal medical advice. Clinic protocols and insurance coverage vary. Sources: Pennsylvania Department of Health (30 September 2026), AAP RSV policy, CPSC recalls.